ASHPOfficial

This podcast will describe how you can evaluate which activities to pursue and thoughtfully determine which ones will help you achieve sustainable success. It also explores how to approach systematically evaluating an opportunity to optimize efficiency.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast episode traces the unique professional journey of Jasper (Jay) Watkins, III. A retired Lieutenant Colonel in the U.S. Army, Watkins recently took office as a member of the Gwinnett County, Georgia Commission. Listeners will hear highlights from Watkins’ more than two decades in pharmacy practice, his motivation for transitioning to a different aspect of public service, and the ways he thinks pharmacy will influence his time in office.  

 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores the nuances of rate and rhythm control in atrial fibrillation. The Early Rhythm Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) Trial that was published in October 2020 will also be discussed.  For today’s debate, Danielle will promote rhythm control while Riley argues that rate control remains the strategy of choice. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast reviews the newly revised ASHP Guidelines on Emergency Medicine Pharmacist Services.  Originally released in 2011, a group of emergency medicine clinical pharmacy specialist content experts conducted a literature search for updated supporting evidence and updated the recommendations to establish reasonable goals on attainable best practices.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

MCM COVID-19 Presentation: Roadmap to a COVID-19 Vaccine: Clinical Considerations for Ensuring Safety and Efficacy Part 1Vaccine Clinical Trial Design and Vaccine Development During a Pandemic

 

In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

 

 

 

 

In today's episode, we take listeners on a deeper dive of specific details of FDA Emergency Use Authorizations: what they are, what they are not, how they are determined, specific nuances that they may subsequently enact, and how they are determined for approval. The topic is intended to be general around EUA’s, but COVID-19 specific examples are highlighted as well as those that have brought public attention to the EUA process. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This two-part podcast series provides listeners with a review of updates to the diabetes treatment guidelines.  Speakers share an overview of guideline updates, evaluate treatment options, and discuss methods of addressing issues related to affordability and access to medications.   

 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this interprofessional conversation, expert faculty discuss the clinical effects of neuromuscular blocking and reversal agents, including key components of NMB and reversal strategies during the intraoperative phase of care and neuromuscular monitoring. Patient risk factors and mitigation of post-operative complications will also be discussed.

To learn more about neuromuscular blockade and reversal visit www.ashpadvantage.com/nmbreversal/

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

February 7-14 is the Congenital Heart Defects (CHD) Awareness Week.  Join members of ASHP’s Pediatric Section Advisory Group as they discuss CHD, the care of children and adults with CHD, the role of pharmacists in the care of patients with CHD, and general clinical pearls for caring for these patients.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.